Drugs / ASP5502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06544642 | Aug 2024 → Mar 2026 | Sjogren syndrome | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP5502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06544642 ↗ |
| Route | Oral | “Oral” NCT06544642 ↗ |